Galmed Pharmaceuticals (GLMD) Projected to Post Earnings on Wednesday

Posted by Tyrone Williams on Mar 29th, 2026

Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) is projected to release its results before the market opens on Wednesday, April 1st. Analysts expect Galmed Pharmaceuticals to post earnings of ($0.51) per share and revenue of $1.2990 million for the quarter.

Galmed Pharmaceuticals Price Performance

GLMD stock opened at $0.50 on Monday. The firm has a market capitalization of $2.77 million, a P/E ratio of -1.58 and a beta of 0.40. Galmed Pharmaceuticals has a 52-week low of $0.41 and a 52-week high of $2.68. The company’s 50 day simple moving average is $0.65 and its 200-day simple moving average is $0.98.

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Citadel Advisors LLC purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 3.05% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors own 76.14% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Reduce”.

View Our Latest Stock Report on Galmed Pharmaceuticals

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.